Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer

Breast cancer is the most frequent and lethal tumor in women and finding the best therapeutic strategy for each patient is an important challenge. PARP inhibitors (PARPis) are the first, clinically approved drugs designed to exploit synthetic lethality in tumors harboring BRCA1/2 mutations. Recent e...

Descripción completa

Detalles Bibliográficos
Autores principales: Palleschi, Michela, Tedaldi, Gianluca, Sirico, Marianna, Virga, Alessandra, Ulivi, Paola, De Giorgi, Ugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346118/
https://www.ncbi.nlm.nih.gov/pubmed/34360649
http://dx.doi.org/10.3390/ijms22157884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346118/
https://www.ncbi.nlm.nih.gov/pubmed/34360649
http://dx.doi.org/10.3390/ijms22157884

Ejemplares similares